|
Aspirin-Myocardial Infarction Study (AMIS) Clinical Trials Data presented on Clinical Trials Search isn't meant to be a substitute for qualified health advice, calls or treatment using a genuine doctor. We are not docs. Always consult your dr. on Aspirin-Myocardial Infarction Study (AMIS) conditions. Clinical Trials Search.org is a site dedicated to listing clinical research studies in human subjects. Aspirin-Myocardial Infarction Study (AMIS) Clinical research trials and Aspirin-Myocardial Infarction Study (AMIS) healthcare trials occur in a lot of of places throughout the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the potency of new drugs. The intent of the studies / undertakings is to figure out certain human medical questions. Clinical trials are a popular means for mDs, government agencies, and private sector corporations to locate remedies for all kinds of circumstances, including Aspirin-Myocardial Infarction Study (AMIS). Aspirin-Myocardial Infarction Study (AMIS) Clinical Trials and other clinical trials allow volunteers to obtain health treatment alternatives before they are available to the masses. Many times the participants undergo treatment for free, and sometimes they are paid for their time. Occasionally there is a cost for a Aspirin-Myocardial Infarction Study (AMIS) clinical trial. Participants typically obtain the most effective healthcare available for their Aspirin-Myocardial Infarction Study (AMIS) condition. Dangers are a reality, nonetheless, and can include extra or frequent mD trips, medical hazards (potentially life-endangering), and/or the treatment being uneffective. Trials are federally regulated with rigid guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > Aspirin-Myocardial Infarction Study (AMIS)  Aspirin-Myocardial Infarction Study (AMIS)
Aspirin-Myocardial Infarction Study (AMIS)
For Condition: Cardiovascular Diseases,Coronary Disease,Heart Diseases,Myocardial Infarction,Myocardial Ischemia
Status: Completed
Sponsor(s): National Heart, Lung, and Blood Institute (NHLBI) ,
Synopsis: To determine whether the daily administration of 1 gm of aspirin to individuals with a documented myocardial infarction would result in a significant reduction in mortality over a three year period.
Details: BACKGROUND: It had been postulated that thrombosis plays a major role in the late stages of coronary artery occlusion. Platelet aggregation is a large component in the formation of arterial thrombi. Theoretically, an agent which prevents the aggregation of platelets would be of value in people with coronary artery disease. Aspirin, in small doses, inhibits platelet aggregation for prolonged periods of time, and therefore might be expected to prevent or retard the occlusion of coronary arteries. This would be reflected in a decrease in the incidence of myocardial infarction and a decrease in mortality due to coronary artery disease. Several studies had given preliminary evidence that regular administration of aspirin may be of benefit to patients with known coronary artery disease. A National Heart and Lung Institute-sponsored study, the Coronary Drug Project, ran a pilot trial of aspirin and placebo in men with previous myocardial infarctions. Preliminary results from this trial demonstrated its feasibility and led NHLBI to sponsor a more definitive controlled study of the benefit of aspirin in the secondary prevention of coronary heart disease. An Institute Planning Committee met four times between October 1974 and April 1975 and developed a protocol, manual of operations, and data collection forms. Recruitment of patients began in June 1975, with the first patient randomized on July 2, 1975. Patients who were randomized had been seen at the AMIS Clinical Center for two initial visits and one baseline visit and were free of any reasons for exclusion, such as the current use of anticoagulants and a history of adverse reactions to aspirin. Patients took acetaminophen at times when they would normally take aspirin. Follow-up was for a minimum of 3 years, with each patient seen at 4-month intervals and monitored for side effects and various nonfatal events, including cardiovascular problems. The primary endpoint was mortality. Annually, a detailed history was obtained and a complete physical examination performed. The study involved 30 clinical centers, a coordinating center, and a central laboratory. The study completed patient recruitment in the scheduled one year period. A total of 4,524 post-MI patients were enrolled by the 30 clinical centers. Three-year minimum patient follow-up ended in August 1979. DESIGN NARRATIVE: Randomized, double-blind, fixed sample. Eligible patients were assigned to a treatment group receiving 1 gm of aspirin daily (the equivalent of three standard aspirin tablets) or to a control group receiving a placebo.
Eligibility:
Study Type: Interventional, Prevention, Randomized, Double-Blind
Minimum Age/Maximum Age: 30 Years/69 Years
Genders: Both
Protocol Entry Criteria: Men and women, ages 30 to 69. Had a documented myocardial infarction.
Total Enrollment:
Location and Contact Information:
Overall Study Official:
AllanBarker, , Salt Lake Clinic Research Foundation
Additional Information:
Study ID Numbers: 10;
Study Start Date: October 1974
Record last reviewed: February 2002
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00000491
Other Cardiovascular Diseases Studies:
1. Improving Hypertension Care for Inner City Minorities
2. Physical Activity and Childhood Obesity
3. Self-Scored Cardiovascular Disease Risk Appraisal
4. Epidemiology of Body Mass Index Rebound
5. Western Collaborative Group Study (WCGS): 25-Year Follow-up of Cardiovascular Disease Morbidity and Mortality
Related Studies:
Other Cardiovascular Diseases Clinical Trials
Other Clinical Trials
Other Clinical Trials
Aspirin-Myocardial Infarction Study (AMIS)
|
|
|
|
|
|
|
|
